May 15, 2025 11:05am EDT MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
May 14, 2025 10:15am EDT MAIA Biotechnology Announces Director Participation in Recent Private Placement
Apr 01, 2025 8:30am EDT MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
Mar 25, 2025 8:46am EDT MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
Mar 20, 2025 9:20am EDT MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
Mar 19, 2025 11:00am EDT MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
Feb 27, 2025 8:51am EST MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
Feb 26, 2025 8:47am EST MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
